BR9801685A - Mutante de birnavírus birnavírus vacina contra uma infecção por birnavírus em animais processo para determinar uma infecção por birnavírus em um animal kit de teste diagnóstico e uso da falta de expressão de proteína vp5 nativa por um mutante de birnavírus - Google Patents

Mutante de birnavírus birnavírus vacina contra uma infecção por birnavírus em animais processo para determinar uma infecção por birnavírus em um animal kit de teste diagnóstico e uso da falta de expressão de proteína vp5 nativa por um mutante de birnavírus

Info

Publication number
BR9801685A
BR9801685A BR9801685A BR9801685A BR9801685A BR 9801685 A BR9801685 A BR 9801685A BR 9801685 A BR9801685 A BR 9801685A BR 9801685 A BR9801685 A BR 9801685A BR 9801685 A BR9801685 A BR 9801685A
Authority
BR
Brazil
Prior art keywords
birnavirus
mutant
infection
native
lack
Prior art date
Application number
BR9801685A
Other languages
English (en)
Other versions
BR9801685B1 (pt
Inventor
Heinrich Dieter Lutticken
Egbert Mundt
Adriaan Anthonius Wilhelm Loon
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR9801685A publication Critical patent/BR9801685A/pt
Publication of BR9801685B1 publication Critical patent/BR9801685B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR9801685A 1997-05-26 1998-05-25 birnavìrus mutante e vacina contra uma infecção de ibdv em animais. BR9801685B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201599 1997-05-26

Publications (2)

Publication Number Publication Date
BR9801685A true BR9801685A (pt) 1999-05-04
BR9801685B1 BR9801685B1 (pt) 2011-10-18

Family

ID=8228373

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9801685A BR9801685B1 (pt) 1997-05-26 1998-05-25 birnavìrus mutante e vacina contra uma infecção de ibdv em animais.

Country Status (9)

Country Link
US (1) US7022327B1 (pt)
JP (1) JP4316025B2 (pt)
AT (1) ATE252153T1 (pt)
AU (1) AU725129B2 (pt)
BR (1) BR9801685B1 (pt)
CA (1) CA2238659C (pt)
DE (1) DE69818913T2 (pt)
ES (1) ES2209052T3 (pt)
PT (1) PT887412E (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485940B2 (en) * 2000-07-07 2002-11-26 Akzo Nobel N.V. Broad spectrum infectious bursal disease virus vaccine
ES2217967B1 (es) * 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
US7491399B2 (en) * 2005-06-23 2009-02-17 University Of Maryland Biotechnology Institute In Ovo vaccine against infectious bursal disease
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
EP2101797B1 (en) * 2006-12-01 2015-08-26 HepC Terápia Kereskedelmi és Szolgáltató Zártkörüen Müködö Részvénytársaság Compositions and methods for the treatment of viral hepatitis
US20090246226A1 (en) * 2008-03-28 2009-10-01 Zeon Corporation Avian vaccines possessing a positive marker gene
CN102382396B (zh) * 2011-09-29 2013-07-17 芜湖海杉型材有限公司 一种塑料管材及其制备方法
CN102504433B (zh) * 2011-10-09 2014-03-19 南京大学 纳米凹凸棒土复合型pvc阻燃剂和pvc阻燃材料及其制法
KR20210068602A (ko) * 2016-06-02 2021-06-09 조에티스 서비시즈 엘엘씨 감염성 기관지염에 대한 백신

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8902087A (nl) * 1989-08-17 1991-03-18 Stichting Tech Wetenschapp Niet-natuurlijk voorkomend pseudorabiesvirus en vaccins die dit bevatten.
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5279965A (en) * 1991-04-05 1994-01-18 Keeler Jr Calvin L Recombinant infectious laryngotracheitis virus
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
US5690937A (en) * 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
CA2257823A1 (en) * 1996-07-15 1998-01-22 Government Of The United States Of America As Represented By The Secreta Ry Of The Department Of Health And Human Services National Institutes Of Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Also Published As

Publication number Publication date
AU6900298A (en) 1998-11-26
US7022327B1 (en) 2006-04-04
ES2209052T3 (es) 2004-06-16
AU725129B2 (en) 2000-10-05
PT887412E (pt) 2004-03-31
CA2238659C (en) 2010-12-14
BR9801685B1 (pt) 2011-10-18
DE69818913D1 (de) 2003-11-20
JP4316025B2 (ja) 2009-08-19
CA2238659A1 (en) 1998-11-26
JPH114683A (ja) 1999-01-12
ATE252153T1 (de) 2003-11-15
DE69818913T2 (de) 2004-08-19

Similar Documents

Publication Publication Date Title
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
BR9801685A (pt) Mutante de birnavírus birnavírus vacina contra uma infecção por birnavírus em animais processo para determinar uma infecção por birnavírus em um animal kit de teste diagnóstico e uso da falta de expressão de proteína vp5 nativa por um mutante de birnavírus
UY26783A1 (es) Antígenos de estreptococo.
BRPI0519241A2 (pt) agonistas, composiÇÕes, mÉtodos e usos de glp-1
BR8905851A (pt) Processo para a deteccao de uma infeccao por aids em seres humanos;composicao de proteina de involucro do virus de aids;e kit de teste utilizavel na administracao intradermica para deteccao de uma infeccao por aids
BR9605153B1 (pt) vacina de combinação, e, kit de vacinação.
SG153829A1 (en) Identifying virally infected and vaccinated organisms
ES2162917T3 (es) Mejoras en o relativas al suministro de peptidos.
ATE145564T1 (de) Anordnung zur bestrahlung von laserstrahlen
BR0016066A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
ATE365749T1 (de) Humane peptide/proteine, die das töten von zellen,einschliesslich lymphoide tumorzellen, herbeiführen oder bewirken
ES2144399T3 (es) Clonado del adn de virus de anemia de los pollos.
ES2071979T3 (es) Metodo para detectar alteraciones en el hueso y en otros tejidos conectivos en humanos y animales.
PT909388E (pt) Ensaios imunologicos para encefalopatias espongiformes
PT946730E (pt) Mutantes de toxina estreptococica c e metodos de utilizacao
BRPI9916549B8 (pt) Composição farmacêutica, proteína, polinucleotídeo
HUP0100130A2 (hu) Rekombináns Mycoplasma hyopneumoniae vakcina
ATE322906T1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
EA199800352A1 (ru) ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА
DE60135632D1 (de) Hochexpression und herstellung von recombinanter s-adenosyl homocysteinase mit hochspezifischer aktivität und verbesserte testverfahren für s-adenosylmethionine (sam)
BR9808251A (pt) Proteìna protetora ou fragmento antigênico da mesma, processo que usa um modelo de desafio ou animal ex vivo, sequência de nucleotìdeos isolada ou sua sequência complementar, célula hospedeira ou sistema de expressão ou vetor, proteìna recombinante, vacina, uso de uma proteìna ou fragmento da mesma, processo para testar uma vacina, anticorpo, teste diagnóstico, e, uso de uma vacina.
BR9509276A (pt) Processos para produzir uma bactéria entérica testar um agente antimicrobiano potencial detectar anticorpos de um hospedeiro para bactéria enterica e bactéria enterica em um animal ou amostra biologica deste produzir anticorpos antibacterianos e estimular uma imuno-resposta em um animal bactéria entérica tendo propriedades antigênicas aumentadas vacina e estojo de teste diagnostico para detectar um hospediro de anticorpos para bacteria enterica ou para detectar bactéria enterica
DE60035485D1 (de) IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407
WO2023066229A3 (en) Recombinant classical swine fever virus e2 protein with b/c domain swapping
BR132017028144E8 (pt) Proteína recombinante, kit para diagnóstico da leishmaniose visceral humana e canina, composição vacinal contra leishmaniose e usos

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: INTERVET INTERNATIONAL B.V. (NL)

Free format text: TRANSFERIDO DE: AKZO NOBEL N.V

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/10/2011, OBSERVADAS AS CONDICOES LEGAIS.

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 15A, 16A, 17A, 18A, 19A, 20A, 21A E 22A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.